Literature DB >> 686888

Antibiotic concentration in human wound fluid after intravenous administration.

D H Bagley, J Mac Lowry, R M Beazley, C Gorschboth, A S Ketcham.   

Abstract

Since the wound is the most common focus of infection in the surgical patient, adequate levels of antibiotic within the wound ar essential. This study examines the concentrations of antibiotic achieved in human wounds. Fluid was collected at timed intervals on the first postoperative day from the wounds of 56 patients receiving antibiotics after regional lymph node dissection. Antibiotic concentration was determined by bioassay. Six antibiotics were studied: cephalothin, cefazolin, cephapirin, oxacillin, ampicillin and clindamycin. The cephalosporins and penicillins showed similar patterns of appearance in the wound fluid. The peak level occurred early (1--1 1/2 hours) with subsequent slow decrease. Clindamycin produced nearly constant levels in wound fluid. The concentration of each antibiotic in wound fluid surpassed the serum levels after 2.5 hours. At the dosages studied each antibiotic produced wound fluid concentrations greater than the MIC for most susceptible organisms. Higher doses provided higher wound fluid levels. The rate of appearance and the levels achieved should be considered in the choice of antibiotics in the surgical subject.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686888      PMCID: PMC1396737          DOI: 10.1097/00000658-197808000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  SODIUM AMPICILLIN: ABSORPTION AND EXCRETION OF INTRAMUSCULAR AND INTRAVENOUS DOSES IN NORMAL YOUNG MEN.

Authors:  T C EICKHOFF; J W KISLAK; M FINLAND
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

2.  The role of prophylactic antibiotic therapy in control of staphylococcal infections following cancer surgery.

Authors:  A S KETCHAM; J H BLOCH; D T CRAWFORD; J E LIEBERMAN; R R SMITH
Journal:  Surg Gynecol Obstet       Date:  1962-03

Review 3.  Influence of binding on the pharmacologic activity of antibiotics.

Authors:  C M Kunin; W A Craig; M Kornguth; R Monson
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

4.  Concentration of selected intravenously administered antibiotics in experimental surgical wounds.

Authors:  J W Alexander; N S Sykes; M M Mitchell; M W Fisher
Journal:  J Trauma       Date:  1973-05

5.  Treatment of anaerobic infections with lincomycin and clindamycin.

Authors:  J G Bartlett; V L Sutter; S M Finegold
Journal:  N Engl J Med       Date:  1972-11-16       Impact factor: 91.245

6.  A method for measurement of antibiotics in human interstitial fluid.

Authors:  J S Tan; A Trott; J P Phair; C Watanakunakorn
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

7.  Pharmacology of cefazolin in human volunteers.

Authors:  P Nicholas; B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol       Date:  1973 Aug-Sep       Impact factor: 3.126

8.  Pharmacokinetic studies of clindamycin phosphate.

Authors:  R M DeHaan; C M Metzler; D Schellenberg; W D Vandenbosch
Journal:  J Clin Pharmacol       Date:  1973 May-Jun       Impact factor: 3.126

9.  Laboratory studies with a new cephalosporanic acid derivative.

Authors:  D R Chisholm; F Leitner; M Misiek; G E Wright; K E Price
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

10.  Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals.

Authors:  L R Fare; P Actor; C Sachs; L Phillips; M Joloza; J F Pauls; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

View more
  8 in total

1.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Pharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injury.

Authors:  J L Segal; S R Brunnemann; I M Eltorai
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Treatment with the Pseudomonas aeruginosa Glycoside Hydrolase PslG Combats Wound Infection by Improving Antibiotic Efficacy and Host Innate Immune Activity.

Authors:  Matthew J Pestrak; Perrin Baker; Sheri Dellos-Nolan; Preston J Hill; Daniel Passos da Silva; Holly Silver; Ira Lacdao; Deepa Raju; Matthew R Parsek; Daniel J Wozniak; P Lynne Howell
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Surgical Revision Promotes Presence of Enterococcus spp. in Abdominal Superficial Surgical Site Infections.

Authors:  Matthias Mehdorn; Woubet Tefera Kassahun; Norman Lippmann; Uwe Scheuermann; Linda Groos; Dorina Buchloh; Boris Jansen-Winkeln; Ines Gockel
Journal:  J Gastrointest Surg       Date:  2021-10-18       Impact factor: 3.452

5.  Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy?

Authors:  Elias Polykandriotis; Raymund E Horch; Matthias Jost; Andreas Arkudas; Frieder Kees; Marweh Schmitz
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

6.  Antibiotic penetration into normal and inflamed tissues as reflected by peripheral lymph.

Authors:  T L Roberts; J W Futrell; M A Sande
Journal:  Ann Surg       Date:  1979-04       Impact factor: 12.969

7.  Studies of cefotaxime serum concentrations during surgery under general anaesthesia and its passage to the wound fluid after surgery for breast cancer.

Authors:  T Ueda; K Sakai; M Fujimoto
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Penetration of cefoperazone into surgical wound drainage in patients undergoing head and neck surgery.

Authors:  R R Muder; V L Yu; J Johnson; P Thearle; J Lyon; W Diven
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.